ImmunityBio (IBRX) Equity Average (2016 - 2025)
Historic Equity Average for ImmunityBio (IBRX) over the last 11 years, with Q3 2025 value amounting to -$547.5 million.
- ImmunityBio's Equity Average rose 2403.49% to -$547.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$547.5 million, marking a year-over-year increase of 2403.49%. This contributed to the annual value of -$538.0 million for FY2024, which is 378.84% down from last year.
- ImmunityBio's Equity Average amounted to -$547.5 million in Q3 2025, which was up 2403.49% from -$581.1 million recorded in Q2 2025.
- Over the past 5 years, ImmunityBio's Equity Average peaked at -$151.9 million during Q1 2021, and registered a low of -$720.8 million during Q3 2024.
- In the last 5 years, ImmunityBio's Equity Average had a median value of -$498.8 million in 2023 and averaged -$457.7 million.
- Its Equity Average has fluctuated over the past 5 years, first plummeted by 685094.94% in 2021, then surged by 2403.49% in 2025.
- Quarter analysis of 5 years shows ImmunityBio's Equity Average stood at -$216.9 million in 2021, then crashed by 102.58% to -$439.5 million in 2022, then fell by 13.51% to -$498.8 million in 2023, then decreased by 23.62% to -$616.6 million in 2024, then increased by 11.21% to -$547.5 million in 2025.
- Its Equity Average was -$547.5 million in Q3 2025, compared to -$581.1 million in Q2 2025 and -$540.3 million in Q1 2025.